The retreat of corporate venture funding?
Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.
Quiet times return for biopharma takeouts
The first quarter of 2021 saw fewer deals than any in recent memory.
AACR 2021 – still awaiting validation, Sanofi keeps on buying
The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.
Big pharma freshens up
Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol.
Big pharma’s key catalysts in the second quarter
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
